Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.
HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.
The prevalence is higher than what has been seen in other studies, which could represent a true difference in prevalence, or reflect limitations of the database.
Subcutaneous efgartigimod PH20 SC is effective and tolerable for the treatment of CIDP, providing a convenient alternative to intravenous and other older treatments.